JP2024524534A5 - - Google Patents

Info

Publication number
JP2024524534A5
JP2024524534A5 JP2024500133A JP2024500133A JP2024524534A5 JP 2024524534 A5 JP2024524534 A5 JP 2024524534A5 JP 2024500133 A JP2024500133 A JP 2024500133A JP 2024500133 A JP2024500133 A JP 2024500133A JP 2024524534 A5 JP2024524534 A5 JP 2024524534A5
Authority
JP
Japan
Prior art keywords
modified
polypeptide
polypeptide according
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524534A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/056367 external-priority patent/WO2023281485A1/en
Publication of JP2024524534A publication Critical patent/JP2024524534A/ja
Publication of JP2024524534A5 publication Critical patent/JP2024524534A5/ja
Pending legal-status Critical Current

Links

JP2024500133A 2021-07-09 2022-07-09 炎症性疾患及び自己免疫疾患の治療のための修飾il-2ポリペプチド Pending JP2024524534A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163219995P 2021-07-09 2021-07-09
US202163219989P 2021-07-09 2021-07-09
US63/219,989 2021-07-09
US63/219,995 2021-07-09
PCT/IB2022/056367 WO2023281485A1 (en) 2021-07-09 2022-07-09 Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2024524534A JP2024524534A (ja) 2024-07-05
JP2024524534A5 true JP2024524534A5 (cg-RX-API-DMAC10.html) 2025-07-16

Family

ID=82701753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500133A Pending JP2024524534A (ja) 2021-07-09 2022-07-09 炎症性疾患及び自己免疫疾患の治療のための修飾il-2ポリペプチド

Country Status (7)

Country Link
US (2) US12173062B2 (cg-RX-API-DMAC10.html)
EP (2) EP4367132A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024524534A (cg-RX-API-DMAC10.html)
KR (1) KR20240034221A (cg-RX-API-DMAC10.html)
AU (1) AU2022306974A1 (cg-RX-API-DMAC10.html)
CA (1) CA3222357A1 (cg-RX-API-DMAC10.html)
WO (2) WO2023281483A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
ES2464532T3 (es) 2001-04-19 2014-06-03 The Scripps Research Institute Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
JP5275566B2 (ja) 2003-06-18 2013-08-28 ザ スクリプス リサーチ インスティチュート 反応性非天然アミノ酸遺伝コード付加
WO2005019415A2 (en) 2003-07-07 2005-03-03 The Scripps Research Institute Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2006332809A1 (en) 2005-12-30 2007-07-12 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
WO2010085495A1 (en) * 2009-01-21 2010-07-29 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
EP2780463A4 (en) 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
SI2890402T1 (sl) 2012-08-31 2019-07-31 Sutro Biopharma, Inc. Modificirane aminokisline vsebujoče acido skupino
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3004062B1 (en) 2013-05-24 2017-07-19 SynAffix B.V. Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
EP3650038A1 (en) 2013-06-19 2020-05-13 Massachusetts Institute of Technology In vivo targeting of cells with ligand-conjugated particles
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3097080A1 (en) 2014-01-24 2016-11-30 SynAffix B.V. Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
PT3134123T (pt) 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
WO2016115168A1 (en) 2015-01-12 2016-07-21 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
JP7299021B2 (ja) 2015-09-11 2023-06-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 生体関連の直交性サイトカイン/受容体ペア
RS62040B1 (sr) * 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
EP4631529A3 (en) 2016-06-28 2026-03-11 Ventana Medical Systems, Inc. Application of click chemistry for signal amplification in ihc and ish assays
EP3272864A1 (en) 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
CA3061467A1 (en) 2017-04-28 2019-10-24 Ajinomoto Co., Inc. Compound having affinity substance to soluble protein, cleavable portionand reactive group, or salt thereof
US20200362058A1 (en) 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US20190023760A1 (en) * 2017-07-24 2019-01-24 Eth Zurich Method for preparing interleukin-2 or interleukin-2 analogues
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
AU2018337671B2 (en) 2017-09-19 2021-03-04 Paul Scherrer Institut Transglutaminase conjugation method and linker
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
EP3720871A4 (en) 2017-12-06 2021-09-15 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたil-2 fc融合タンパク質
US11970537B2 (en) 2017-12-26 2024-04-30 Nanjing GenScript Biotech Co., Ltd. Fusion protein dimer using antibody Fc region as backbone and use thereof
JP7102670B2 (ja) 2018-01-25 2022-07-20 アイ-エムエービー バイオファーマ ユーエス リミテッド 抗pd‐l1抗体とil‐7との融合
CA3115461A1 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
CN108503714A (zh) 2018-04-10 2018-09-07 浙江科途医学科技有限公司 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
EP4406975A3 (en) 2018-06-14 2024-11-13 Ajinomoto Co., Inc. Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
JP7413999B2 (ja) 2018-06-14 2024-01-16 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
AU2019288496B2 (en) 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
US12522640B2 (en) 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
WO2020061142A1 (en) 2018-09-18 2020-03-26 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3117853A1 (en) 2018-10-29 2020-05-07 1Globe Biomedical Co., Ltd. Novel rationally designed protein compositions
JPWO2020090979A1 (ja) 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
TW202034945A (zh) 2018-12-21 2020-10-01 大陸商江蘇恆瑞醫藥股份有限公司 一種人白細胞介素2變體或其衍生物
CN113613679A (zh) 2019-03-19 2021-11-05 保罗·谢勒学院 基于甘氨酸的接头的转谷氨酰胺酶缀合方法
KR20220009380A (ko) 2019-05-17 2022-01-24 선전 엔듀어링 바이오테크 리미티드 표적 면역요법을 위한 절단 가능한 사이토카인이 있는 이중특이적 t-세포 연계체
AU2020279240A1 (en) * 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
AU2020285636A1 (en) * 2019-05-24 2021-11-04 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof
KR20260089650A (ko) * 2019-07-12 2026-06-15 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
PH12022550165A1 (en) * 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
EP4013775A1 (en) 2019-08-12 2022-06-22 Askgene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
AU2020329933A1 (en) 2019-08-15 2022-03-24 Cytimm Therapeutics, Inc. Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof
CN110642934B (zh) 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
JP2022552371A (ja) * 2019-10-15 2022-12-15 モデルナティエックス インコーポレイテッド 免疫調節ポリペプチドをコードするmRNA及びその使用
AU2020403148A1 (en) * 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
US11648296B2 (en) 2019-12-13 2023-05-16 Synthekine, Inc. IL-2 orthologs and methods of use
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ose免疫治療公司 包含il-7變體之雙官能分子
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
CA3162320A1 (en) 2019-12-23 2021-07-01 Alexander V. SHIROKOV Methods of preparing n6-((2-azidoethoxy)carbonyl)lysine
KR20220140514A (ko) 2020-01-10 2022-10-18 브라이트 피크 테라퓨틱스 아게 변형된 il-2 폴리펩타이드 및 그의 용도
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
AR121713A1 (es) 2020-03-31 2022-06-29 Hanmi Pharm Ind Co Ltd Nuevos análogos de il-2 inmunoestimulantes
CA3168460A1 (en) 2020-04-15 2021-10-21 F. Hoffmann-La Roche Ag Immunoconjugates
KR102986821B1 (ko) 2020-04-22 2026-07-06 머크 샤프 앤드 돔 엘엘씨 인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
AU2021402065A1 (en) 2020-12-17 2023-06-29 Boehringer Ingelheim International Gmbh Bifunctional anti-pd1/il-7 molecules
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
JP2024504372A (ja) 2021-01-22 2024-01-31 エルピス・バイオファーマシューティカルズ 抗pd-l1モノクローナル抗体及びインターロイキン15(il-15)、インターロイキン15受容体15アルファまたはインターロイキン2との融合タンパク質

Similar Documents

Publication Publication Date Title
TW496870B (en) Compositions methods for stimulating megakaryocyte growth and differentiation
JP2025063029A5 (cg-RX-API-DMAC10.html)
JP2707241B2 (ja) 代用血漿剤
JPWO2019131964A5 (cg-RX-API-DMAC10.html)
DK2598526T3 (en) CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS
JP2021073174A5 (cg-RX-API-DMAC10.html)
JP2010513506A5 (cg-RX-API-DMAC10.html)
JP4753867B2 (ja) ヒトil−18を含むコンジュゲートおよびその置換変異体
JP2023052258A5 (cg-RX-API-DMAC10.html)
JPH06504794A (ja) 新規アミリン作動薬ペプチドおよびその使用
JP2020172505A5 (cg-RX-API-DMAC10.html)
JP2023554379A5 (cg-RX-API-DMAC10.html)
Kazim et al. Prediction and conformation by synthesis of two antigenic sites in human haemoglobin by extrapolation from the known antigenic structure of sperm-whale myoglobin
JP2002514418A5 (cg-RX-API-DMAC10.html)
JP2023543262A5 (cg-RX-API-DMAC10.html)
JP2004521123A5 (cg-RX-API-DMAC10.html)
CN1527839A (zh) 免疫原性减弱的经修饰人脑衍生的神经营养因子(bdnf)
JP2710653B2 (ja) 新規ポリペプチド及びその製造法
KR20030074790A (ko) 감소된 면역원성을 갖는 개질 인터루킨-1 수용체길항제(il-1ra)
JP2024507795A (ja) グルカゴン様ペプチド-1受容体アンタゴニスト
US5939063A (en) Modified forms of granulocyte macrophage-colony stimulating factor as antagonists
KR20030082961A (ko) 감소된 면역원성을 갖는 개질 프로타민
JP2008517998A5 (cg-RX-API-DMAC10.html)
CN1494551A (zh) 免疫原性减弱的经修饰粒细胞巨噬细胞集落刺激因子(gm-csf)
CN118772240B (zh) 一种芋螺多肽、药物组合物及其应用